Therapeutic drug monitoring for antiretroviral therapy: Usefulness and limitations

AIDS Reviews

Volumn 2, Issue 2, 2000, Pages 67-75

  De Requena, D G ^a   Jimenez Nacher, I ^a   Soriano, V ^a  

^a NONE   (Spain)

Author keywords

Antiretroviral therapy; Drug levels; Therapeutic drug monitoring

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DRUG BLOOD LEVEL; DRUG MONITORING; GENETIC VARIABILITY; HEALTH CARE MANAGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT CARE; REVIEW;

EID: 0033931650     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. CDC guidelines for the use of antiretroviral agents in HIV infected adults and adolescents
3. Use of virologic markers in clinical practice
4. Factors that predict incomplete virological response to protease inhibitor-based anti-retroviral therapy
5. Virological failure and adherence to antiretroviral therapy in HIV-infected patients
6. Drug monitoring of antiretroviral therapy for HIV-1 infection: Method validation and results of a pilot study
7. HIV drug resistance and insufficient drug plasma levels as factors determining antiretroviral treatment failure
8. Clinical pharmacokinetics of antiretroviral drugs
9. Differential phosphorilation of azidothymidine, dideoxycitidine and dideoxyinosine in resting and activated peripheral blood mononuclear cells
10. Alteration of thymidin kinase activity in cells treated with an antiviral agent
11. Activity of thymidin kinase in PBMCs of HIV-1 infected patients correlates with disease progression
12. Impact of pharmacology on antiretroviral therapy
13. Viral and cellular factors for resistance against antiretroviral agents
14. Intracellular phosphorilation of stavudine (d4T) and 3TC correlates with their antiviral activity in naive and zidovudine experience patients
15. Plasma and intracellular triphosphate (NRTI-TP) concentrations of ZDV, D4T, and 3TC in patients with HIV infection
16. Concentration-controlled zidovudine therapy
17. Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy
18. Plasma concentrations of saquinavir determine HIV-RNA response over a 48-week period
19. Low plasma levels of indinavir (IDV) are highly predictive of virological treatment failure in patients using IDV-containing triple therapy
20. Indinavir concentrations and antiviral effect
21. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
22. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir
23. Virologic failure, resistance and plasma drug measurements in induction-maintenance therapy trial (ANRS 072, Trilege)
24. The effect of high-dose saquinavir on viral load and CD4+ T-cell in HIV-infected patients
25. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
26. Virologic response-plasma drug concentration relationship in phase III study of nelfinavir mesylate (Viracept)
27. Antiviral effect and pharmacokinetic interaction between Nevirapine and Indinavir in persons infected with Human Immunodeficiency Virus Type 1
28. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
29. Independent benefit of sufficient drug levels and genotypic analysis in salvage therapy: Pharmacological data of the Viradapt study
30. Relevance of protease inhibitor plasma levels in patients treated with genotypic adapted therapy: Pharmacological data from the viradapt study
31. Relevance of protease inhibitors (PI) plasma levels in patients treated with genotypic adapted therapy
32. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as a part of triple therapy (CHEESE study)
33. Indinavir pharmacokinetics are related to efficacy and toxicity
34. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
35. Toxicity and the exposure to protease inhibitors in a quadruple drug regimen in HIV infected patients
36. The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring
37. Spontaneous Adherence (ADH) Audits (SAA) predicts viral suppression in the REACH cohort.
38. Incidence and predictors of virologic failure of antiretroviral therapy in a community based cohort
39. The value of patient reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group
40. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMS caps
41. Drug concentration heterogeneity facilitates the evolution of drug resistance
42. Serum protease inhibitor level as a marker of adherence to HAART: Correlation with self reported adherence and with HIV RNA
43. Self reported adherence to HAART correlates with protease inhibitors plasma levels but not with viral load in heavily pre-treated patients
44. Prospective monitoring of indinavir or saquinavir level in hair samples from 132 HIV-infected patients and correlation with response to highly active antiretroviral therapy and selection of HIV-resistant mutants
45. Indinavir concentration in hair from patients receiving highly active antiretroviral therapy
46. Saliva as a possible specimen for monitoring compliance and plasma levels in patients treated with indinavir
47. Relation of saliva and plasma levels in patients treated with ritonavir and indinavir
48. Resistance to Efavirenz (Sustiva) in vivo
49. A resistance and cross resistance profile for SUSTIVA (Efavirenz, DMP 266)
50. High-dose Nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with Human Immunodeficiency Virus Infection
51. A randomized, double-blind trial comparing combinations of Nevirapine, Didanosine, and Zidovudine for HIV-infected patients. The INCAS trial
52. High exposure to Nevirapine is associated with higher initial HIV-1 clearance rate, a higher likelihood to reach undetectability and prolonged suppression of HIV-1 replication
53. Population pharmacokinetics of Efavirenz in phase II studies and relationship with efficacy
54. Rapid determination of Nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection
55. Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
56. High-performance liquid chromatography method for analyzing the antiretroviral agent efavirenz in human plasma
57. Failure of antiretroviral therapy due to malabsorption disorders and their impact on HIV-resistance
58. Pl trough and peak plasma concentrations during HAART
59. Drug monitoring of saquinavir during monotherapy or in combination with Ritonavir in patients with chronic liver disease
60. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
61. The effect of increasing α1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors
62. Impact of mutation, plasma protein binding and pharmacokinetics on clinical efficacy of the HIV-1 non nucleoside reverse transcriptase inhibitor, DMP 266
63. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
64. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
65. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein
66. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
67. HIV-1 protease inhibitors are substrates for the MDR-1 multidrug transporter
68. Cellular influx/eflux of protease inhibitors in vivo
69. Human immunodeficiency virus protease inhibitors serve as a substrate for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
70. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes
71. Human immunodeficiency virus-induced expression of P-glycoprotein
72. Cross resistance to anti-HIV nucleoside analogues in multidrug-resistant human cells
73. Abnormal expression of a 170 kDa P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection
74. Effect of stavudine and zidovudine on expression of the P-glycoprotein drug transporter in HIV-1 infected patients
75. The limited value of therapeutic drug monitoring in HIV infection